Page 34 - டோ ஜோன்ஸ் நிலைத்தன்மை குறியீடுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia

F. Hoffmann-La Roche Ltd Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia The REMDACTA clinical trial of Actemra/RoActemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone Roche will submit the REMDACTA results to a peer-reviewed journal Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiv

United statesNathalie meetzLevi garrawayDaniel grotzkyActemra roactemraPatrick barthKarsten kleineChugai pharmaceutical co ltdGilead sciencesHead of global product developmentGilead sciences incRoche groupPharmaceuticals industryRoche group media relationsNew england journalChief medical officer

Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Roche s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems

F. Hoffmann-La Roche Ltd Roche’s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems Roche’s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems For patients living in areas with limited healthcare resources, WHO prequalification ensures access to the highest quality diagnostics Access to broader reliable diagnostic solutions helps healthcare communities working to expedite and increase disease elimination programs Roche’s Global Access Program provides innovative diagnostic solutions improving disease and patient management for those most in need Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the cobas® HIV-1 and cobas® HCV Tests for use on the cobas® 6800/8800 Systems have been awarded World Health Organization (WHO) prequalification. WHO prequalification helps regulators and procurers in low and middle-income countries to identify products that

United statesNathalie meetzDaniel grotzkyThomas schineckerPatrick barthKarsten kleineClinton health access initiativeWorld health organizationRoche global access programGlobal fundRoche groupPharmaceuticals industryRoche group media relationsGlobal access programPlasma separation cardGlobal access

Roche s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems

Roche s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesNathalie meetzDaniel grotzkyThomas schineckerPatrick barthKarsten kleineClinton health access initiativeWorld health organizationRoche global access programGlobal fundRoche groupPharmaceuticals industryRoche group media relationsGlobal access programPlasma separation cardGlobal access

F Hoffmann-La Roche Ltd: Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia

F Hoffmann-La Roche Ltd: Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNathalie meetzJon kaspar bayardLevi garrawayDaniel grotzkyKarl mahlerSabine borngrGerard tobinBruno eschliBirgit masjostLoren kalmLisa tuomiActemra roactemraPatrick barthKarsten kleineChugai pharmaceutical co ltd

Valmet Oyj : introduces its climate program – Forward to a carbon neutral future

Valmet Oyj s press release on March 10, 2021 at 9:00 a.m. EET Valmet introduces its climate program - Forward to a carbon neutral future - in the company s Capital Markets Day on March 10, 2021. The program continues Valmet s comprehensive work for sustainability. Valmet s climate program includes ambitious CO₂emission reduction targets and concrete actions for the whole value chain, including Valmet s own operations, the supply chain, and the use of Valmet s technologies by its customers. The program is aligned with the Paris Climate Agreement s 1.5-degree pathway and the United Nations Sustainable Development Goals, and Valmet is in process to send its climate targets to the Science Based Targets Initiative for validation.

France generalLaura puustjScience based targets initiativeCorporate communicationsUnited nations sustainable development goalsCapital markets dayParis climate agreementPasi laineDow jones sustainability indicesValmet oyj stock exchangePress releaseThe valmt fi4000074984பிரான்ஸ் ஜநரல்அறிவியல் அடிப்படையிலானது இலக்குகள் முயற்சிபெருநிறுவன தகவல்தொடர்புகள்ஒன்றுபட்டது நாடுகள் நிலையான வளர்ச்சி இலக்குகள்